Infliximab, adalimumab nearly tied for pediatric IBD infection risk
Infliximab and adalimumab exhibited similar infection risk profiles in children and adolescents with inflammatory bowel disease when used as initial biologic therapy, according to study results published in JAMA Network Open.
Researchers reported that serious infections were “rare” with use of either biologic, with slightly higher rates of outpatient infections.
“Infliximab and adalimumab are the only biologic therapies approved by the FDA for both Crohn’s disease and ulcerative colitis in children, and both are commonly used as initial biologic treatments,” Ning Lyu, PhD, MS, a postdoctoral